Gan & Lee Receives Clinical Trial Approval for GLR1075 Injection
核心洞察
Gan & Lee received a Drug Clinical Trial Approval Notification from China's NMPA for its investigational GLR1075 (搜索) injection.
The cleared indication is hepatic cirrhosis with hypoalbuminemia (搜索), with the application submitted on July 3, 2026.
GLR1075 (搜索) is a recombinant human albumin preparation, a humanized recombinant protein drug developed independently by Gan & Lee.
Gan & Lee (603087.SH) has received a Drug Clinical Trial Approval Notification from China's National Medical Products Administration (搜索) for its investigational drug GLR1075 (搜索) injection. The application, submitted on July 3, 2026, met the relevant requirements for drug registration, and approval was granted to conduct clinical trials in hepatic cirrhosis with hypoalbuminemia (搜索).
GLR1075 (搜索) injection is a recombinant human albumin preparation independently developed by Gan & Lee and is classified as a humanized recombinant protein drug. Its active ingredient, recombinant human albumin, has the same amino acid sequence and a similar spatial conformation to natural human serum albumin.
According to the company, the recombinant protein can perform the core physiological functions of albumin, including correcting colloid osmotic pressure imbalance and improving pathological microenvironments.